OTCMKTS:SOLTF Nxera Pharma (SOLTF) Stock Price, News & Analysis $6.37 +0.19 (+2.99%) As of 11:48 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Nxera Pharma Stock (OTCMKTS:SOLTF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nxera Pharma alerts:Sign Up Key Stats Today's Range$6.37▼$6.3750-Day Range$5.28▼$7.9452-Week Range$4.90▼$7.94Volume100 shsAverage Volume3,680 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily; and strategic research and development partnership with PrecisionLife to auto-immune disorders with the potential to identify new drug targets for the treatment of chronic conditions. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan. Read More Receive SOLTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nxera Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SOLTF Stock News HeadlinesNxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug DiscoveryJune 10, 2026 | globenewswire.comNxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South KoreaJune 1, 2026 | globenewswire.comBlackRock's CEO is calling this "the next major evolution"Larry Fink, CEO of BlackRock - the world's largest asset manager with $10 trillion under management - is calling this 'the next major evolution in market infrastructure.' He's referring to a complete overhaul of America's financial system, and by law the entire $382 trillion U.S. financial system must migrate onto it by April 2027. BlackRock launched a fund on this new infrastructure and hit $2.8 billion in assets in three months. JPMorgan is running $2 billion a day through it. Goldman Sachs, Citi, Bank of America, and Wells Fargo have all announced full integration. The digital fuel powering this grid is up 374% over the last five years.June 22 at 1:00 AM | Awesomely, LLC (Ad)Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026May 26, 2026 | globenewswire.comNxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A FinancingMay 11, 2026 | globenewswire.comNxera Files Patent Infringement Action in Relation to its miniG Platform TechnologyMay 8, 2026 | globenewswire.comNxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of InsomniaApril 14, 2026 | globenewswire.comNxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with SchizophreniaApril 12, 2026 | markets.businessinsider.comSee More Headlines SOLTF Stock Analysis - Frequently Asked Questions How have SOLTF shares performed this year? Nxera Pharma's stock was trading at $5.48 at the beginning of the year. Since then, SOLTF shares have increased by 16.2% and is now trading at $6.37. How do I buy shares of Nxera Pharma? Shares of SOLTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/22/2026Next Earnings (Estimated)8/07/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:SOLTF CIKN/A Webwww.sosei.com Phone(135) 210-3290FaxN/AEmployees360Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (OTCMKTS:SOLTF) was last updated on 6/22/2026 by MarketBeat.com Staff. From Our PartnersBlackRock's CEO is calling this "the next major evolution"Larry Fink, CEO of BlackRock - the world's largest asset manager with $10 trillion under management - is calli...Awesomely, LLC | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredBofA: Digital Dollar Coming 2025-2030But most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to ...Money Pickle | SponsoredI’m shouting ‘Buy Now’ before this stock soarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, ...Chaikin Analytics | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredBofA: Digital Dollar Coming 2025-2030The US government has ONLY ONE mathematical escape from $38.4T in debt: explosive AI-driven GDP growth. AI ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nxera Pharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nxera Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SOLTF Stock Alerts